Expert Insights On Decentralized Trials

41. Pharma Companies Are Tapping Digital Health For Improved Patient Outcomes 8/11/2022

    Smarter diagnostic tools and a growing role for remote care will be of huge importance in the new paradigm. The pharma industry, which is already growing its role in delivering hybrid solutions combining therapies with diagnostic and smart solutions and devices, could play a significant role here.

42. How AI/ML Is Helping Clinical Researchers Investigate Alzheimer's 7/28/2022

    Like many cognitive conditions, Alzheimer’s disease can cause changes to a person’s speech and language. Artificial intelligence (AI) and machine learning scientists are working on automating speech assessments to detect the disease earlier and improve understanding of the efficacy of novel treatments. 

43. Your Guide To Harnessing Clinical Trial Sensor Data Better 7/26/2022

    Technological advances in wearables and sensors are speeding the development of digital measures and endpoints. This sensor data is often in native formats unique to each sensor technology and in proprietary clouds owned by the manufacturer. To address this challenge, the Digital Medicine Society released a set of open-access toolkits to support the successful scaling of sensor data to drive better clinical decisions.

44. Designing A Phase 3 Clinical Trial In Rare Dermatology: Lessons Learned 7/15/2022

    Rare dermatologic disease R&D is growing at a much faster rate than other fields in dermatology. Even before the data readout from our Phase 2b study, we began formulating several possible Phase 3 trial designs and asked scientific, operational, and regulatory questions. Here are our lessons learned.

45. Decentralized Clinical Trials: Are We Using The Best Terminology For Patients? 7/12/2022

    There is a need within the clinical trials community for a broad term to describe clinical trials that make use of digital health tech and other methods for better accessibility to participants. However, is a single term as helpful for patients as it is for clinical trial professionals?

46. Diversity In Clinical Research Execution And Participation 6/27/2022

    In this article we compare the 2020 and 2021 result of the WCG Avoca Industry Survey, which explores industry respondents’ views on patient diversity in clinical research participation.

47. Decentralized Clinical Trials: Key Considerations For Sites & PIs 6/21/2022

    As we work to harness the benefits of hybrid and DCTs, sites and investigators must have processes that allow for the acceptance of DCTs and successful implementation. As these policies are under development, the vital viewpoints of sites and PIs are largely overlooked. This article shares these vital viewpoints of sites and PIs.

48. How To Navigate Drug Repurposing And Bridging Studies 6/17/2022

    Rarely is a new drug the optimal version of that product, and drug companies often search for new uses, new users, or new dosage forms of an approved product after it hits the market in what is commonly known as “drug repurposing.” To receive FDA approval for a repurposed drug, companies must submit bridging studies that often include clinical trials. 

49. Best Practices For Designing Patient-Centric Decentralized Clinical Trials 4/12/2022

    Decentralized clinical trials are not universally applicable to all phases of a trial and therapeutic areas. The recommendations in this article may bring decentralized and hybrid trials to a more tangible and realistic view and, in essence, make them more executable.

50. 2021 Clinical Research Site Survey Findings: A Year In Flux 3/24/2022

    Since its inception in 2012, the Society for Clinical Research Sites (SCRS) has conducted an annual survey of clinical research site community members to derive insights, reveal trends, and ensure the site perspective is represented. This article summarizes the 2021 survey's findings.